C OSBORNE to Antineoplastic Agents
This is a "connection" page, showing publications C OSBORNE has written about Antineoplastic Agents.
Connection Strength
0.476
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.103
-
Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22.
Score: 0.052
-
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6.
Score: 0.049
-
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):271-6.
Score: 0.035
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
Score: 0.026
-
Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4.
Score: 0.021
-
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32.
Score: 0.021
-
Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):805-9.
Score: 0.019
-
Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs. 1989 Jul; 7(2-3):243-5.
Score: 0.018
-
Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
Score: 0.017
-
Antitumor activity and murine pharmacokinetics of parenteral acronycine. Cancer Res. 1989 Jan 15; 49(2):340-4.
Score: 0.017
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.013
-
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9.
Score: 0.013
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.012
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.011
-
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol. 1982; 8(3):261-5.
Score: 0.010
-
Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981; 1(2):121-3.
Score: 0.010
-
Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
Score: 0.006
-
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res. 2011 Sep 01; 17(17):5559-61.
Score: 0.005
-
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol. 1987 May; 23(5):545-51.
Score: 0.004
-
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
Score: 0.003
-
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
Score: 0.003
-
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells (1981). 1982; 2(1):34-44.
Score: 0.003
-
Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat. 1981; 1(2):131-4.
Score: 0.002
-
Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat. 1981; 1(2):141-8.
Score: 0.002